OP023 A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn’s disease (CD)
Bibliographic record
Abstract
Vedolizumab (VDZ) is a gut-selective humanised immunoglobulin G1 monoclonal antibody that prevents the trafficking of T-lymphocytes into the gastrointestinal submucosa by antagonising the interaction of alpha4beta7 integrin with its ligand, mucosal addressin cell adhesion molecule 1 (MAdCAM-1).1 VDZ has demonstrated statistically significant differences in clinical remission from placebo in patients (patients) with moderately to severely active Crohn’s disease (CD),2 but endoscopic healing was not previously assessed. The present study evaluated the effect of VDZ on endoscopic remission and healing in patients with CD. Patients with moderately to severely active CD (≥3 months; CD Activity Index [CDAI] 220-450; Simple Endoscopic Score for CD [SES-CD] ≥7; ≥1 mucosal ulceration on centrally read endoscopy) who had previously experienced treatment failure with corticosteroids, immunomodulators, and/or at least one tumour necrosis factor-alpha (TNF) antagonist were enrolled. Patients received VDZ 300 mg intravenously at weeks 0, 2, 6, and then every 8 weeks for 26 weeks, followed by a 26-week treatment extension period. The primary endpoint was endoscopic remission (SES-CD ≤4) at week 26, assessed by centrally read ileocolonoscopy. Key secondary endpoints included endoscopic response (SES-CD ≥50% reduction from baseline) and complete endoscopic healing (absence of ulcerations) at week 26. Subgroup analyses stratified by TNF antagonist exposure status were performed for all endpoints and by disease severity for endoscopic remission only. Of the 101 patients enrolled, 55% had previously failed at least one TNF antagonist (TNF-F), and 46% were categorised as having severe endoscopic activity at entry (SES-CD score of >15). Endoscopic remission rates at week 26 were 12% overall, 20% in TNF antagonist naïve (TNF-N), and 6% in TNF-F patients, respectively (Table 1). Endoscopic remission at week 26 was achieved in 17% of patients with moderate endoscopic activity (SES-CD score of 7–15) compared with 7% of patients with severe disease. Endoscopic response and complete endoscopic healing rates at week 26 are shown in Table 1. Endoscopic outcomes at week 26 by TNF antagonist status. VDZ demonstrated the ability to induce endoscopic remission and healing in a refractory population. TNF-N patients were more likely to achieve endoscopic remission and healing than those with previous treatment failure to a TNF antagonist. 1. Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther, 2009:330;864-–75, 330. 2. Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med, 2013;369:711–21.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.002 | 0.003 |
| Insufficient payload (model declined to judge) | 0.006 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".